# US 2015/0148339 A1 · Gastrin antagonists for treatment and prevention of osteoporosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148339 A1
- Document ID: US20150148339A1
- Status: Published application
- Kind: A1
- Application number: 14/550,233
- Filed: 2014-11-21
- Published: 2015-05-28
- Earliest claimed: 2013-11-22
- Assignees: Clifton Life Sciences LLC
- Applicants: CL BioSciences LLC
- Inventors: Irvin Mark Modlin; Mark Kidd
- Web page: https://patentgrep.com/patent/US20150148339A1

## CPC

- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The provided embodiments are based in some aspects on the demonstration herein of a role for gastrin in regulating the aging gut-ovary axis and effects of targeting gastrin activity in reversing gastrin-mediated bone loss. Provided are methods, compositions and agents, including gastrin antagonists, for treatment, amelioration, and prevention of bone diseases and conditions. Methods for treating a bone disease or condition associated with hypergastrinemia in a subject in need thereof may comprise administering to the subject at least one dose of a therapeutically effective amount of a gastrin receptor-targeting agent, thereby treating the bone disease or condition associated with hypergastrinemia.

## Claims

### Claim 1

A method for treating a bone disease or condition associated with hypergastrinemia in a subject in need thereof, comprising administering to the subject at least one dose of a therapeutically effective amount of a gastrin receptor-targeting agent, thereby treating the bone disease or condition associated with hypergastrinemia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the gastrin receptor-targeting agent is administered over a treatment time period to resolve the bone disease or condition associated with hypergastrinemia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one dose of the gastrin receptor-targeting agent is administered to the subject over the duration of hypergastrinemia, irrespective of the cause of hypergastrinemia.

### Claim 4 (depends on 1)

The method of claim 1, wherein the bone disease or condition associated with hypergastrinemia is a disease or condition characterized as osteoporosis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the gastrin receptor-targeting agent is a selective CCK2 receptor antagonist.

### Claim 6 (depends on 5)

The method of claim 5, wherein the selective CCK2 receptor antagonist is YF476.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a female with decreased ovarian function or ovarian failure.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject: (a) is a female with decreased ovarian function or ovarian failure, and (b) has hypergastrinemia.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering the gastrin receptor-targeting agent with a therapeutically effective amount of a proton pump inhibitor (PPI) or histamine 2 receptor (H2R) antagonist, simultaneously or sequentially, in any order.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the gastrin receptor-targeting agent is 10-25 nanomolar.

### Claim 11 (depends on 8)

The method of claim 8, wherein the hypergastrinemia is neoplastic hypergastrinemia or hypergastrinemia associated with acid suppressive pharmacology.

### Claim 12 (depends on 10)

The method of claim 10, wherein the therapeutically effective amount of the gastrin receptor-targeting agent is between 0.2-14 μg/kg body weight of the subject.

### Claim 13 (depends on 1)

The method of claim 1, wherein the gastrin receptor-targeting agent is administered to the subject in a single dose by subcutaneous injection.

### Claim 14 (depends on 1)

The method of claim 1, wherein the gastrin receptor-targeting agent is administered to the subject by intravenous injection.

### Claim 15 (depends on 1)

The method of claim 1, wherein the gastrin receptor-targeting agent is administered to the subject orally in a dose ranging from 20-100 mg.

### Claim 16 (depends on 9)

The method of claim 9, wherein the PPI or H2R antagonist is orally administered to the subject.
